Sahni Kanika, Singh Sanjay, Dogra Sunil
Department of Dermatology and Venereology, AIIMS, New Delhi, India.
Department of Dermatology, Venereology and Leprology, PGIMER, Chandigarh, India.
Indian Dermatol Online J. 2018 May-Jun;9(3):149-158. doi: 10.4103/idoj.IDOJ_281_17.
Dermatophytes are amongst the most common causative agents of fungal infections worldwide and widespread in the developing countries. Various studies have found the significantly rising trend of this infection in India especially in last 4-5 years. The growing epidemic of recurrent/chronic dermatophytosis has led to the need for newer antifungal agents and/or preparations. Furthermore, resistance to commonly used topical and oral antifungals has increased alarmingly. Significantly increasing resistance has led to state of anxiety in physicians and significant distress to the patients socially, emotionally, and financially. Newer formulations or newer derivatives of existing drug classes and few newer drug classes are being developed to tackle this menace. Other forms of local therapies including lasers and photodynamic therapy are still in developmental phase and still need to be optimized in terms of dosing schedule, frequency of use and duration of therapy. Moreover, cost of these therapies remained most important obstacle in developing countries like India. We are hereby reviewing the newer formulations of topical therapies and drugs/interventions in experimental phase.
皮肤癣菌是全球最常见的真菌感染病原体之一，在发展中国家广泛存在。多项研究发现，这种感染在印度呈显著上升趋势，尤其是在过去4至5年。复发性/慢性皮肤癣菌病的日益流行导致需要更新的抗真菌药物和/或制剂。此外，对常用局部和口服抗真菌药物的耐药性惊人地增加。耐药性的显著增加使医生感到焦虑，并给患者带来社会、情感和经济上的巨大痛苦。正在开发现有药物类别的新制剂或新衍生物以及少数新的药物类别来应对这一威胁。包括激光和光动力疗法在内的其他局部治疗形式仍处于开发阶段，在给药方案、使用频率和治疗持续时间方面仍需优化。此外，这些治疗的成本仍然是印度等发展中国家最重要的障碍。我们在此回顾局部治疗的新制剂以及处于实验阶段的药物/干预措施。
